COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Cash Flow Analysis including operating cash flow, investing cash flow, financing cash flow, free cash flow, cash flow from operations, cash flow from investing, cash flow from financing. Compare cash flow against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Cash Flow Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.

Operating Cash Flow per Share

-23.74

Negative OCF/share while Healthcare median is 0.00. Seth Klarman would examine if a turnaround is realistic.

Free Cash Flow per Share

-43.16

Negative FCF/share while Healthcare median is -0.01. Seth Klarman would question if the business is too capex-heavy.

Capex-to-Operating Cash Flow

-81.81%

Negative ratio while Healthcare median is 0.00%. Seth Klarman would examine if negative OCF or unusual accounting drives this figure.

Income Quality Ratio (OCF / Net Income)

-0.74

Negative ratio while Healthcare median is 0.83. Seth Klarman might see a severe mismatch of earnings and cash.

Operating Cash Flow-to-Sales Ratio

-2.11%

Negative ratio while Healthcare median is 0.00%. Seth Klarman would suspect deeper operational issues or near-zero revenue.

Select Chart Metric: